Laura Garcia-Gerique
Overview
Explore the profile of Laura Garcia-Gerique including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
345
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pascual-Pasto G, McIntyre B, Hines M, Giudice A, Garcia-Gerique L, Hoffmann J, et al.
Nat Commun
. 2024 Aug;
15(1):7141.
PMID: 39164224
Novel chimeric antigen receptor (CAR) T-cell approaches are needed to improve therapeutic efficacy in solid tumors. High-risk neuroblastoma is an aggressive pediatric solid tumor that expresses cell-surface GPC2 and GD2...
2.
Garcia-Gerique L, Nefedova Y
Oncotarget
. 2023 Mar;
14:258-260.
PMID: 36961884
No abstract available.
3.
Lin C, Garcia-Gerique L, Bonner E, Mastio J, Rosenwasser M, Cruz Z, et al.
Cancer Res Commun
. 2023 Mar;
3(3):420-430.
PMID: 36923707
Significance: We identified a novel mechanism by which myeloid cells promote myeloma progression independently of the adaptive immune system. Specifically, we discovered a novel role of S100A8/S100A9, the most abundant...
4.
Fu S, Deng H, Bertolini I, Perego M, Chen E, Sanseviero E, et al.
Cancer Immunol Res
. 2022 Dec;
11(3):278-289.
PMID: 36548516
Pathologically activated neutrophils (PMN) with immunosuppressive activity, which are termed myeloid-derived suppressor cells (PMN-MDSC), play a critical role in regulating tumor progression. These cells have been implicated in promoting tumor...
5.
Pascual-Pasto G, McIntyre B, Shraim R, Buongervino S, Erbe A, Zhelev D, et al.
J Immunother Cancer
. 2022 Dec;
10(12).
PMID: 36460335
Background: Antibody-drug conjugates (ADCs) that deliver cytotoxic drugs to tumor cells have emerged as an effective and safe anticancer therapy. ADCs may induce immunogenic cell death (ICD) to promote additional...
6.
Kim R, Hashimoto A, Markosyan N, Tyurin V, Tyurina Y, Kar G, et al.
Nature
. 2022 Nov;
612(7939):338-346.
PMID: 36385526
Ferroptosis is a non-apoptotic form of regulated cell death that is triggered by the discoordination of regulatory redox mechanisms culminating in massive peroxidation of polyunsaturated phospholipids. Ferroptosis inducers have shown...
7.
Deng H, Lin C, Garcia-Gerique L, Fu S, Cruz Z, Bonner E, et al.
Cancer Res
. 2022 Sep;
82(19):3561-3572.
PMID: 36069973
Significance: PAD4 regulates tumor progression by promoting neutrophil migration and can be targeted with a small molecule inhibitor to suppress tumor growth and metastasis and increase efficacy of immune checkpoint...
8.
Garcia-Gerique L, Garcia M, Garrido-Garcia A, Gomez-Gonzalez S, Torrebadell M, Prada E, et al.
BMC Cancer
. 2022 Jun;
22(1):669.
PMID: 35715791
Background: The bone marrow (BM) is the most common site of dissemination in patients with aggressive, metastatic neuroblastoma (NB). However, the molecular mechanisms underlying the aggressive behavior of NB cells...
9.
Campbell K, Rossi F, Adams J, Pitsidianaki I, Barriga F, Garcia-Gerique L, et al.
Nat Commun
. 2019 May;
10(1):2311.
PMID: 31127094
Metastasis underlies the majority of cancer-related deaths yet remains poorly understood due, in part, to the lack of models in vivo. Here we show that expression of the EMT master...
10.
Pascual-Pasto G, Bazan-Peregrino M, Olaciregui N, Restrepo-Perdomo C, Mato-Berciano A, Ottaviani D, et al.
Sci Transl Med
. 2019 Jan;
11(476).
PMID: 30674657
Retinoblastoma is a pediatric solid tumor of the retina activated upon homozygous inactivation of the tumor suppressor VCN-01 is an oncolytic adenovirus designed to replicate selectively in tumor cells with...